AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03555214 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Placebo treatment:~The patient remains supine and the therapist sits on a stool at the bedside with the forearms resting on the couch. Both hands are placed on the posterolateral part of the patient's head and the position is maintained for 10 minutes without exerting any force or movement.
Study NCT03555214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy based on structural techniques
Description: Manual Therapy:~1. Technique of manipulation of the occipito-atlanto-axoidea joint (OAA).~2. Articulation technique of the high cervical spine (C0-C1).~3. Postero-anterior articular technique of C2-C7 in supine position.~4. Postero-anterior articular technique of C2-C7 in prone position.~5. Manipulative technique of the flapper C7-T1.~6. Dorsal spinal manipulative technique (T1-T8).~7. Lumbosacral global manipulative technique.
Study NCT03555214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy based on soft tissues and structural techniques
Description: Manual Therapy:~1. Technique of suboccipital inhibition.~2. Cranial frontal technique.~3. Cranial sphenoid technique.~4. Cranial fourth ventricle technique.~5. Antero-posterior abdominal-sacral technique.~6. Technique of manipulation of the occipito-atlanto-axoidea joint (OAA).~7. Articulation technique of the high cervical spine (C0-C1).~8. Postero-anterior articular technique of C2-C7 in supine position.~9. Postero-anterior articular technique of C2-C7 in prone position.~10. Manipulative technique of the flapper C7-T1.~11. Dorsal spinal manipulative technique (T1-T8).~12. Lumbosacral global manipulative technique.
Study NCT04038814 — intervention group
Intervention type: PROCEDURE
Intervention: Routine prevention of VAP
Description: Enhanced hand hygiene protocol, tube cuff pressure monitoring ( set on 25-30 mm Hg) every 12 hours and every time when we suspected under or over distention, fast withdrawal of sedation, moderate supportive mechanical ventilation ( tidal volume (VT) 5-8 ml/kg ideal body weight (IBW), positive end expiratory pressure (PEEP) 3-5 cmH2O, Plateau pressure (Ppl) \< 25 cm H2O, normocapnia ), Proton Pump Inhibitors (PPIs) reduction, Selective oral decontamination (SOD) every 8 hours - 0,2% chlorhexidine digluconate mouthwash, Closed Tracheal Suction System (CTSS) - changed every 7 day, 30-45% lifting of the thorax
Study NCT04038814 — intervention group
Intervention type: PROCEDURE
Intervention: Modified prevention of VAP
Description: 3 modifications of the routine bundle in the prevention of VAP:~* Endotracheal tube ( Shiley Evac Endotracheal tube with TaperGuard Cuff) and tracheostomy tubes (Tracheostomy Tube Cuffed Seal Guard) instead of regular tubes,~* Automatic, continuous tube cuff pressure monitoring ( Covidien Shiley M Pressure Control Automatic Cuff Controller ( 25-30 mmHg),~* Automatic continuous subglottic secretion drainage
Study NCT02731755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oat
Description: The study oat intervention products will consist of 67.7g oatflake and 22.5g oatbran concentrate.
Study NCT02731755 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 60g cream of rice
Study NCT03364595 — intervention group
Intervention type: PROCEDURE
Intervention: plate fixation
Description: ORIF of the radial head fracture
Study NCT03364595 — intervention group
Intervention type: PROCEDURE
Intervention: replacement
Description: replacement of the radial head fracture
Study NCT00423098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate sodium
Description: Mycophenolate sodium as administered orally for 2 weeks at 1440mg daily and then increased to 2160mg daily for 22 weeks.
Study NCT00423098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium
Description: Mycophenolate sodium as administered orally for 2 weeks at 1440mg daily and then increased to 2160mg daily for 22 weeks.
Study NCT00423098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral prednisone or prednisone equivalent was started on Day 4 and subsequently tapered every 2 weeks according to the patient's weight.
Study NCT00423098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral prednisone or prednisone equivalent was started on Day 4 and subsequently tapered every 2 weeks according to the patient's weight.
Study NCT00423098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: All patients received bolus therapy with 0.5 g of intravenous Methylprednisolone per day for 3 consecutive days.
Study NCT00423098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: All patients received bolus therapy with 0.5 g of intravenous Methylprednisolone per day for 3 consecutive days.
Study NCT02284555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Description: Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.
Study NCT03786991 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04616963 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg
Description: Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation.
Study NCT04616963 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Emtricitabine Tenofovir Alafenamide 200/25 mg
Description: Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation
Study NCT00566514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-ribose
Description: 5 grams administered orally TID
Study NCT00566514 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dextrose
Description: 5 grams orally TID
Study NCT02474394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mcgrath
Description: The patient will be intubated using McGrath series 5 video laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
Study NCT02474394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh
Description: The patient will be intubated using Macintosh laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
Study NCT01016522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KetoCal
Description: Ketogenic Diet food via gastrostomy tube - 80% fat, 17% protein, 3% carbohydrates
Study NCT02180763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammanorm
Description: Sub-Q IgG
Study NCT01489982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light box (Litebook company)
Description: Light therapy will be administered daily for a duration of 30 minutes, starting two hours (+/- 1 hour) prior to usual bedtime
Study NCT01489982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT and sleep hygiene
Description: 6 weekly sessions totalling 90 minutes
Study NCT01489982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxepin and Zopiclone
Description: Zopiclone 3.75 mg at h.s., increasing to 7.5 mg after one week if insufficient clinical effects ( and no troublesome side effects) or Doxepin 5 mg at h.s. followed by increase up to 10 mg after the first week if insufficient clinical effect (and no troublesome side effects)
Study NCT01489982 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light box ( Litebook company)
Description: The intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles
Study NCT01751958 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection
Description: Epidural steroid injection
Study NCT01594333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week
Study NCT00419913 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone
Description: DHEA 25 mg tid
Study NCT00419913 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dehydroepiandrosterone
Description: DHEA 25 mg tid
Study NCT01757756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pf-05175157
Description: 200-mg administered twice daily for 14 days
Study NCT01757756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo administered twice daily for 14 days
Study NCT01757756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam 3-mg admistered as single doses on Day 0 and Day 11.
Study NCT02156232 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TIPS
Description: TIPS is performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.
Study NCT02156232 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPSS embolization
Description: Embolization of SPSS will be conducted via the same jugular vein before TIPS implantation. The major procedures included (a) angiography of SPSS after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of SPSS with coils of varying diameters or Amplatzer Vascular Plug, which resulted in the SPSS disappearing at postembolization angiography.
Study NCT02546427 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Helical TomoTherapy (HT)
Study NCT02546427 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife SBRT
Study NCT02546427 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Permanent Prostate Implant (PPI)
Study NCT02546427 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy
Study NCT00483158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Finafloxacin hydrochloride
Description: Tablets, oral single dose and multiple dose once daily for 7d
Study NCT00483158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin hydrochloride
Description: Tablets, oral single dose and multiple dose once daily for 7d
Study NCT04706169 — intervention group
Intervention type: DEVICE
Intervention: Surface Electromyography
Description: SEMG was used to measure the amplitude and onset of five shoulder muscle electrical signal, performing glenohumeral abduction. In this movement, the middle deltoid muscle was selected because it is a main motor. The infraspinatus muscle represented the rotator cuff muscle group. The middle deltoid muscle was selected as the representative of shoulder abduction because it is a main motor in this movement. The trapezius muscle and the serratus anterior muscle were chosen as representative established of the ascending scapular rotator muscles.
Study NCT02827994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neurophysiology of pain education and exercises
Description: Pain neurophysiology education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. It was delivered in small groups (4 to 7 participants). A total of 4 sessions were delivered over 4 weeks (1 session per week). Each session took between 45 minutes and 1 hour.~Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular muscles delivered over 3 sessions (the first session covered pain neurophysiology education only). Each exercise was performed in 3 series of 10 repetitions. The number of exercises targeting the same group of muscles increased from one in the 2nd session to 2/3 in the 4th session.
Study NCT03130023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Oximeter with ORI
Description: Pulse oximeter that measure Oxygen Reserve Index
Study NCT03162497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 15mg/g eyedrops
Study NCT03162497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline 100 mg per os
Study NCT00356863 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing awareness to cardiac rehabilitation programs
Description: Increasing awareness to cardiac rehabilitation programs: Before coronary artery bypass grafting (CABG) surgery patients received a face-to-face explanation on their right to participate in cardiac rehabilitation programs (CRPs) under the Israeli Basket of Health Services; they were also provided with a brochure on the benefits of CRP participation and the availability of CRPs throughout the country.
Study NCT00583817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular stent-graft implantation
Description: Endovascular repair of aorta
Study NCT03791905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: chemotherapy drug
Study NCT03791905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: chemotherapy drug
Study NCT03791905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: chemotherapy drug
Study NCT03791905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: chemotherapy drug
Study NCT00873912 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
Study NCT01731717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active monitoring
Description: General physician performs monitoring every 2 weeks using the PHQ-9 depression scale.
Study NCT01731717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bibliotherapy
Description: Patient works with self-help book Selbsthilfe bei Depressionen (Görlitz, 2010) under general physician's supervision.
Study NCT01731717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online self-help
Description: Patient works with online self-help program Deprexis under general physician's supervision.
Study NCT01731717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient psychotherapy
Description: Patient receives outpatient psychodynamic or cognitive-behavioural psychotherapy from a psychotherapist participating in the network.
Study NCT01731717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychiatric treatment
Description: Patient receives treatment from psychiatrist or general physician participating in the network, this includes psychopharmacotherapy. Treatment takes place within routine care, thus psychiatrists or general physicians individually determine the type of medication and are committed to follow the recommendations of the German S3-Guideline/National Disease Management Guideline for Unipolar Depression.
Study NCT01731717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined psychotherapy and psychopharmacological treatment
Description: Patient receives psychotherapy combined with psychopharmacological treatment, if necessary in inpatient setting.
Study NCT01731717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group: treatment as usual
Description: treatment as usual
Study NCT04010019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Facebook Condition
Description: The intervention (enhanced Facebook condition) will consist of several training components that were selected based on pain research and platform affordances. The first component will be psychoeducation on pain neurobiology. Emotional validation training will follow. The third component will consist of facilitating patients' emotional disclosure about their pain journeys and lives. The fourth and final intervention component will include prompts to engage participants in activities that they have been avoiding because of their pain.
Study NCT04010019 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Facebook Condition
Description: The control condition will instruct participants to offer mutual support and will not offer psychosocial intervention.
Study NCT01915719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early non invasive ventilation
Study NCT01915719 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen therapy only
Study NCT02943967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CXL + PRK group
Description: Corneal cross-linking with subsequent photorefractive keratotomy after 6 months was performed in one eye
Study NCT02943967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRK group
Description: Photorefractive keratotomy alone was performed in contra lateral eyes
Study NCT04171024 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham electrical stimulation
Description: A non invasive sham diaphragm electrical stimulation using transcutaneous thoracic probes
Study NCT04171024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous diaphragm electrical stimulation
Description: A non invasive diaphragm electrical stimulation using transcutaneous thoracic probes
Study NCT01591889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinidazole
Description: 500 mg tablet
Study NCT05166681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical wound suturing
Description: single layer surgical wound suturing in comparison with the traditional multi-layer wound suturing
Study NCT05166681 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical wound suturing
Description: single layer surgical wound suturing in comparison with the traditional multi-layer wound suturing
Study NCT01161459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii
Description: Tripterygium wilfordii 120mg/d Prednisone 30mg/d
Study NCT01161459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FK506
Description: capsule
Study NCT03100500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QMF149
Description: QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler
Study NCT03791905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: chemotherapy drug
Study NCT03791905 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: radiotherapy technique
Study NCT02352974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAD-Alum
Study NCT02352974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT03547583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets
Description: Oral use. Vericiguat, which will be started at 2.5 mg at randomization and up-titrated to 5 mg at week 2, and to 10 mg at week 4, with sham titration or up-titration to 15 mg at week 6.
Study NCT00389831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine Nasal Spray
Description: Daily single dose of 62µg, 124µg, and 247µg rotigotine delivered as single puff of nasal spray solution
Study NCT00389831 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: Daily single dose of placebo delivered as single puff of nasal spray solution
Study NCT01040884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ActiSight Needle Guidance System
Description: ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera
Study NCT02011750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Valproate treatment
Description: Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment group, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.